Europe Injectable Drug Delivery Devices Market Size (2024 - 2029)

The Europe injectable drug delivery devices market is experiencing growth driven by the increased demand for needles and syringes due to the COVID-19 pandemic and the subsequent development and approval of vaccines. This demand is further supported by the rising prevalence of chronic diseases, such as diabetes, which boosts the need for convenient injectable solutions like prefilled syringes and autoinjectors. Despite these positive trends, the market's expansion may be hindered by the growing adoption of alternative drug delivery methods.

Home Market Analysis Healthcare Research Device Drug Combination Research Drug Filled Devices Research Drug Filled Devices With Needle Research Europe Injectable Drug Delivery Industry Market Size

Market Size of Europe Injectable Drug Delivery Devices Industry

Europe Injectables Drug Delivery Market Industry Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 10.50 %
Market Concentration Low

Major Players

Europe Injectables Drug Delivery Market Industry Major Players

*Disclaimer: Major Players sorted in no particular order

Europe Injectable Drug Delivery Devices Market Analysis

The Europe injectable drug delivery devices market is expected to register a CAGR of 10.5% over the forecast period, (2022-2027).

The Europe injectable drug delivery devices market has been significantly impacted by the COVID-19 pandemic due to the development of vaccines and treatment against COVID-19 which has increased the demand for needles and syringes in the market. For instance, according to the European Medicines Agency (EMA), many treatment options and vaccines were approved during the study period. For instance, in December 2021, EMA granted authorization for Novavax's COVID-19 vaccine Nuvaxovid to prevent COVID-19 in people from 18 years of age. Also, in January 2022, EMA's human medicines committee (CHMP) approved a scale-up of manufacturing of Vaxzevria (previously COVID-19 Vaccine AstraZeneca). The scale-up of manufacturing of the vaccines and new approvals shows a positive impact on injectable drug delivery devices like needles and syringes which helps in the growth of the market during the study period.

The major growth drivers of the Europe injectable drug delivery devices market are the growing burden of chronic diseases and benefits, and convenience in the usage of the injectables. For instance, as per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in Europe for 2021, 2030, and 2045 were estimated as 7.0%, 8.0%, and 8.7% respectively. There is gradual raise in the prevalence of diabetes in Europe which is expected to increase demand for prefilled syringes and autoinjector-dependent treatments in the forecast period.

However, the growing use of alternative drug delivery methods may restrain market growth over the forecast period.

Europe Injectable Drug Delivery Devices Industry Segmentation

As per the scope of the report, injectable drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a parenteral route of administration. The Europe injectable drug delivery devices market is segmented by Device Type (Conventional Drug Delivery Devices and Self-injectable Drug Delivery Devices [Prefilled Syringes, Injectable Pens, Auto-Injectors, Needle-free Injectors, and Other Device Types]), Therapeutic Application (Cardiovascular Disease, Diabetes, Oncology, Autoimmune Disorders, Hepatitis, and Other Therapeutic Applications), and Geography (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe). The report offers the value (in USD million) for the above segments.

By Devices Type
Conventional Drug Delivery Devices
Self-injectable Drug Delivery Devices
Prefilled Syringes
Injectable Pens
Auto Injectors
Needle-free Injectors
Other Device Types
By Therapeutic Application
Cardiovascular Disease
Diabetes
Oncology
Autoimmune Disorders
Hepatitis
Other Therapeutic Applications
Geography
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Need A Different Region Or Segment?
Customize Now

Europe Injectable Drug Delivery Devices Market Size Summary

The Europe injectable drug delivery devices market is poised for significant growth, driven by the increasing prevalence of chronic diseases and the convenience offered by self-injectable devices. The COVID-19 pandemic has notably accelerated market expansion due to the heightened demand for needles and syringes for vaccine distribution and treatment administration. The approval and scale-up of vaccine manufacturing by the European Medicines Agency have further bolstered the market. The rising incidence of conditions such as diabetes and cancer in Europe underscores the growing need for prefilled syringes and autoinjector-dependent treatments, which are integral to managing these chronic diseases. Despite the potential restraint posed by alternative drug delivery methods, the market is expected to thrive, supported by advancements in technology and increased awareness of self-administration.

The United Kingdom stands out as a significant contributor to the market's growth within Europe, attributed to its sophisticated healthcare system and the rising prevalence of chronic diseases like diabetes. The approval of COVID-19 vaccines and treatments in the UK has also played a crucial role in enhancing the demand for injectable drug delivery devices. The market is moderately competitive, with major international players such as Baxter, Becton, Dickinson and Company, and Novo Nordisk A/S leading the charge. Collaborations and product innovations, such as Stevanato Group's exclusive agreement with Owen Mumford Ltd. for the Aidaptus auto-injector, highlight the dynamic nature of the market. As the demand for efficient and convenient drug delivery systems continues to grow, the Europe injectable drug delivery devices market is expected to experience robust expansion in the coming years.

Explore More

Europe Injectable Drug Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden of Chronic Diseases

      2. 1.2.2 Benefits and Convenience Offered by Self Injectors

    3. 1.3 Market Restraints

      1. 1.3.1 Growing Use of Alternative Delivery Methods

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD Million)

    1. 2.1 By Devices Type

      1. 2.1.1 Conventional Drug Delivery Devices

      2. 2.1.2 Self-injectable Drug Delivery Devices

        1. 2.1.2.1 Prefilled Syringes

        2. 2.1.2.2 Injectable Pens

        3. 2.1.2.3 Auto Injectors

        4. 2.1.2.4 Needle-free Injectors

        5. 2.1.2.5 Other Device Types

    2. 2.2 By Therapeutic Application

      1. 2.2.1 Cardiovascular Disease

      2. 2.2.2 Diabetes

      3. 2.2.3 Oncology

      4. 2.2.4 Autoimmune Disorders

      5. 2.2.5 Hepatitis

      6. 2.2.6 Other Therapeutic Applications

    3. 2.3 Geography

      1. 2.3.1 Germany

      2. 2.3.2 United Kingdom

      3. 2.3.3 France

      4. 2.3.4 Italy

      5. 2.3.5 Spain

      6. 2.3.6 Rest of Europe

Europe Injectable Drug Delivery Devices Market Size FAQs

The Europe Injectable Drug Delivery Devices Market is projected to register a CAGR of 10.5% during the forecast period (2024-2029)

Becton, Dickinson and Company, Baxter, Gerresheimer AG, Lilly and Teva Pharmaceutical Industries Ltd are the major companies operating in the Europe Injectable Drug Delivery Devices Market.

Injectable Drug Delivery Devices Market in Europe Report Snapshots

Europe Injectable Drug Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)